<DOC>
	<DOCNO>NCT03106545</DOCNO>
	<brief_summary>Postoperative analgesia hallux valgus surgery ( bunionectomy ) inconsistent may even result rebound pain ( ankle ) block wear . It hypothesize mixture bupivacaine liposome bupivacaine increase extent duration postoperative analgesia decrease opioid consumption compare bupivacaine alone general anesthesia .</brief_summary>
	<brief_title>Liposome Bupivacaine ANKLE Blocks</brief_title>
	<detailed_description />
	<mesh_term>Hallux Valgus</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>Male female , least 18 year max 65 year age screen Scheduled undergo primary Scarf osteotomy elective hallux valgus American Society Anesthesiologists ( ASA ) physical status 1 , 2 , 3 Female subject must surgically sterile monogamous partner surgically sterile ; least 2 year postmenopausal ; practice abstinence ; use insertable , injectable , transdermal , combination oral contraceptive approve FDA great 2 month prior screen commit use acceptable form birth control duration study 30 day completion study Able demonstrate sensory function exhibit sensitivity cold , pinprick , light touch Able understand English Dutch language , purpose risk study , provide sign date informed consent authorization use protect health information ( PHI ) accordance national local subject privacy regulation Able adhere study visit schedule , complete study assessment . Currently pregnant , nursing , plan become pregnant study within 1 month study drug administration Planned concurrent surgical procedure ( e.g. , bilateral hallux valgus repair ) Concurrent painful physical condition may require analgesic treatment ( NSAID opioid ) postsurgical period pain strictly relate hallux valgus may confound postsurgical assessment ( e.g. , significant pain joint include chronic neuropathic pain , concurrent prior contralateral knee foot surgery ) Previous hallux valgus foot consider surgery History hypersensitivity idiosyncratic reaction amidetype local anesthetic Contraindication bupivacaine , oxycodone , morphine , hydromorphone Chronic daily use longacting opioid medication NSAIDs ( except lowdose aspirin use cardioprotection ) within 24 hour Initiation treatment follow medication within 1 month study drug administration medication ( ) give control pain : selective serotonin reuptake inhibitor ( SSRIs ) , selective norepinephrine reuptake inhibitor ( SNRIs ) , gabapentin , pregabalin ( Lyrica® ) , duloxetine ( Cymbalta® ) . If subject take one medication reason pain control , must stable dose least 1 month prior study drug administration . Current use systemic glucocorticosteroids within 1 month study enrollment Use dexmedetomidine HCl ( Precedex® ) within 3 day study drug administration History impair kidney function , chronic respiratory disease , rheumatoid arthritis , coagulopathy , loss sensation extremity Impaired kidney function ( e.g. , serum creatinine level &gt; 2 mg/dL [ 176.8 µmol/L ] blood urea nitrogen level &gt; 50 mg/dL [ 17.9 mmol/L ] ) impair liver function ( e.g. , serum aspartate aminotransferase [ AST ] level &gt; 3 time upper limit normal ( ULN ) serum alanine aminotransferase [ ALT ] level &gt; 3 time ULN Uncontrolled anxiety , psychiatric , neurological disorder might interfere study assessment Any chronic neuromuscular deficit affect peripheral nerve muscle surgical extremity Any chronic condition disease would compromise neurological vascular assessment Suspected known history drug alcohol abuse within previous year Body weight &lt; 40 kg ( 88 pound ) body mass index &gt; 44 kg/m2 Previous participation EXPAREL study Administration investigational drug within 30 day 5 elimination halflives investigational drug , whichever longer , prior study drug administration , plan administration another investigational product procedure subject 's participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>